Berberine vs Semaglutide
A side-by-side research comparison of Berberine and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Berberine | Semaglutide |
|---|---|---|
| Full name | Berberine HCl | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | OTC supplement | FDA Approved |
| Mechanism | Activates AMP-activated protein kinase (AMPK), the cellular energy sensor, improving insulin sensitivity, reducing hepatic glucose production, lowering LDL cholesterol, and favorably shifting the gut microbiome. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 371.81 Da | 4,114 Da |
| Half-life | ~2.5 hours (poor systemic bioavailability) | 7 days (168 hours) |
| Bioavailability | Low (~5%); improved by dihydroberberine or piperine | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 500 mg, 2-3x per day | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 2-3x daily with meals | Once weekly |
| Route | Oral capsule | Subcutaneous injection |
Berberine reported benefits
- Improved insulin sensitivity
- Lower fasting blood glucose
- Reduced LDL and triglycerides
- AMPK activation (exercise-mimetic)
- Gut microbiome support
- Modest weight/waist reduction
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.